Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Jefferies Reiterates Buy Rating on Mirati Therapeutics (MRTX)
December 6, 2022 8:01 AM ESTJefferies analyst Maury Raycroft reiterated a Buy rating and $149.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "Abstract data strengthen adagrasib's 1L pembro combo profile, removing worst-case scenarios and showing positive differentiation on safety+efficacy vs AMGN. MRTX said we'll... More
Piper Sandler Reiterates Overweight Rating on Mirati Therapeutics (MRTX)
December 6, 2022 8:00 AM ESTPiper Sandler analyst Swapnil Malekar reiterated an Overweight rating and $110.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "ESMO-IO abstract revealed that adagrasib+pembro combo in 1L NSCLC patients showed an ORR of 49%, which came in below the Street expectation of ~55%... More
JPMorgan Reiterates Overweight Rating on Mirati Therapeutics (MRTX)
December 6, 2022 8:00 AM ESTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $94.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "ESMO-IO late-breaking abstracts were published this evening, including an updated look at the phase 2 KRYSTAL-7 trial (adagrasib + pembrolizumab in 1L G12C+ NSCLC). On the whole, we believe the data continue to support the regimens differentiated positioning relative to standard of care and are far more favorable than that of Lumakras + CPI.... More
Morgan Stanley Reiterates Equalweight Rating on Mirati Therapeutics (MRTX)
December 6, 2022 7:59 AM ESTMorgan Stanley analyst Michael Ulz reiterated an Equalweight rating and $100.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "Data in the abstract from the Ph2 K-7 study (adagrasib + pembro) in 1L NSCLC confirm a tolerable safety profile, as expected. That... More
